Corebridge Financial, Inc.
CRBGCorebridge Financial, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved −8.4% in a year while annual EPS moved −118.3% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is topping out (6 weeks in) while the P/BV sits at the 52nd percentile of its own 4-year range. Underneath, the last four quarters read improving, with the the net margin at −1.5%. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Corebridge Financial, Inc. trades at $31.6, losing momentum at the top and 6 weeks into that stage. That is +10.0% against its own 200-day average. It sits at 73% of a 52-week range of $22 to $35. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is losing momentum at the top — week 6 of stage 3. At $31.6 it trades +10.0% versus its 200-day average and sits at 73% of its 52-week range ($22–$35).
Against the market, two honest reads. Cumulative: over the last 3.9 years the stock moved +53% while the S&P 500 moved +100% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
Corebridge Financial, Inc. trades at 1.4× P/BV, mid-range by its own standards (52nd percentile). Its long-run median P/BV is 1.4×, measured across 3.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 1.4× is mid-range by its own standards (52nd percentile), against a long-run median of 1.4× measured over 3.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The honest context for that discount: a bank earning about 2% on its equity is worth less per dollar of book, and the market has priced that in rather than overlooked it. The discount closes only if the returns themselves improve.
🚨 Why the multiple sits where it does: over the past year book value grew while the price moved −8.4% — price and book moved together, holding the multiple in its range.
The price move, decomposed: over 3y, of the +17.5%/yr price move, ~+12.1%/yr came from book-value growth and ~+5.4 pp from the multiple (expanding). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Corebridge Financial, Inc. reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −70.4% latest against +111.5% at its 12-quarter best), ROE holding at 1.8%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −1.2% | −9.2% | — | — |
| Stock price | −8.4% | +17.5% | — | — |
4-Factor Sector Score
44.7/100 — rank 15 of 29 in Asset Management · 55% evidence confidence
Corebridge Financial, Inc. scores 44.7 out of 100 against the 29 companies it is compared with in Asset Management, ranking 15. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 19.1 + 5.2 + 9.8 + 10.6 = 44.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.
Corebridge Financial, Inc. reported $4.0 B of income in the Mar 26 quarter, +10.9% year on year. That is the 3rd straight quarter of year-on-year growth. Over 4 years it has compounded at −5.6% a year. The last full year, FY25, came in at $18.5 B. The last four reported quarters add to $18.9 B.
FY25 revenue came in at $18.5 B (−1.2% on the year), capping 4 years at −5.6% compound. The latest quarter (Mar 26) printed $4.0 B, +10.9% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +24.0% growth against the decade's −5.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +14.6% over the last 4 quarters against −3.7%/yr over the last 8 — accelerating; TTM profit −70.4% vs −69.9%/yr — stabilising.
Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.
Corebridge Financial, Inc.'s net margin is −1.5% in the Mar 26 quarter, +17.0 percentage points against the same quarter a year ago. Across 5 fiscal years the net margin has ranged −2.1% to 39.4%. The current quarter sits inside that band.
The latest quarter's net margin is −1.5%, +17.0 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged −2.1%–39.4%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Corebridge Financial, Inc. posted a net loss of $0.1 B in the Mar 26 quarter. The full FY25 year was a loss of $0.4 B. That loss is 1.5% of the quarter's revenue. The same quarter a year earlier lost $0.7 B. 5 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.1 B, null year on year. On the full year, FY25 printed $−0.4 B (−117.7%).
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for Corebridge Financial, Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
Corebridge Financial, Inc.'s revenue grew −1.2% in FY25 to $18.5 B, so the book is flat. The latest quarter ran +10.9% year on year. The net margin on that income is −1.5%, +17.0 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY25 revenue was $18.5 B, −1.2% on the year, and the latest quarter ran +10.9% year on year. The net margin on that revenue is −1.5% this quarter (+17.0 pp YoY) — growth with a widening margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
Corebridge Financial, Inc. earns a return on equity of −3% in FY25. Its trough over the ladder below was −3% in FY25. On the asset side every $100 of the balance sheet earned about $0.20, which is the return before leverage is applied.
FY25 ROE came in at −3%. On assets, the latest reading is about 0.20% — every $100 the bank deploys earns roughly $0.20 a year. That return is below the bar a bank must clear to compound book value quickly — which is also the honest reason the stock trades where it does.
Why: the ROE ladder shows the move; the deposit-cost and provisioning drivers behind it sit below what we hold.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Corebridge Financial, Inc. paid $0.97 per share over the last four reported quarters, up 4.2% on a year ago. The most recent declaration was $0.25 for Mar 26. Against the current price of $31.6 that is a trailing yield of 3.07%, measured on dividends already paid rather than on a forecast.
Corebridge Financial, Inc. paid $0.97 per share across the last four reported quarters, most recently $0.25 for Mar 26. That is up 4.2% against the same quarter a year earlier. Against the current price of $31.6 the trailing twelve months work out to 3.07% — trailing dividends measured against today's price, not a forward estimate.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
8.0% of Corebridge Financial, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 8.0% of the float is sold short, and at typical trading volumes it would take about 4.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Corebridge Financial, Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Victory Capital Holdings, Inc.VCTR | 66.2/100Favorable setup76% evidence | LEADER | 24.7/35 Income 64.1% · PAT 29.1% 71% evidence | 16.5/25 ROA 3.6% · ROE 6.4% · GNPA — 68% evidence | 7.9/20 P/BV 2.29× · P/BV÷ROE 0.36 70% evidence | 17.1/20 RS sector 21% · RS bench 25.6% · 1Y 45.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 16.5 + 7.9 + 17.1 = 66.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Raymond James Financial, Inc.RJF | 59.0/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.3/35 Income — · PAT — 26% evidence | 15.3/25 ROA 1.4% · ROE 9.7% · GNPA — 68% evidence | 11.0/20 P/BV 2.24× · P/BV÷ROE 0.23 70% evidence | 11.4/20 RS sector -3.3% · RS bench 0% · 1Y 8.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 15.3 + 11 + 11.4 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Affiliated Managers Group, Inc.AMG | 57.8/100Mixed-positive evidence60% evidence | BREAKING OUT | 20.1/35 Income — · PAT — 26% evidence | 14.6/25 ROA 1.6% · ROE 6.1% · GNPA — 68% evidence | 6.9/20 P/BV 2.94× · P/BV÷ROE 0.48 70% evidence | 16.2/20 RS sector 14.9% · RS bench 19.4% · 1Y 81.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 14.6 + 6.9 + 16.2 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4SEI Investments CompanySEIC | 56.7/100Mixed-positive evidence60% evidence | BREAKING OUT | 17.9/35 Income — · PAT — 26% evidence | 17.6/25 ROA 5.2% · ROE 7.7% · GNPA — 68% evidence | 5.9/20 P/BV 4.21× · P/BV÷ROE 0.55 70% evidence | 15.3/20 RS sector 5.7% · RS bench 9.5% · 1Y 19.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 17.6 + 5.9 + 15.3 = 56.7 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 5BlackRock, Inc.BLK | 53.3/100Mixed-positive evidence80% evidence | BASING | 22.9/35 Income 26.5% · PAT 9.2% 81% evidence | 16.4/25 ROA 2.5% · ROE 7.9% · GNPA — 68% evidence | 8.4/20 P/BV 2.64× · P/BV÷ROE 0.33 70% evidence | 5.6/20 RS sector -8.3% · RS bench -5.1% · 1Y 0.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 16.4 + 8.4 + 5.6 = 53.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.3% and the one-year return is 0.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Blackstone Inc.BX | 50.6/100Mixed-positive evidence60% evidence | TURNING | 20.8/35 Income — · PAT — 26% evidence | 18.1/25 ROA 5% · ROE 10.8% · GNPA — 68% evidence | 4.4/20 P/BV 9.7× · P/BV÷ROE 0.9 70% evidence | 7.3/20 RS sector -14.2% · RS bench -11.8% · 1Y -18.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 18.1 + 4.4 + 7.3 = 50.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 7State Street CorporationSTT | 50.3/100Mixed-positive evidence60% evidence | LEADER | 17.7/35 Income — · PAT — 26% evidence | 9.3/25 ROA 0.3% · ROE 3.9% · GNPA — 68% evidence | 7.1/20 P/BV 1.66× · P/BV÷ROE 0.43 70% evidence | 16.2/20 RS sector 18.2% · RS bench 23% · 1Y 66.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 9.3 + 7.1 + 16.2 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Janus Henderson Group plcJHG | 50.0/100Mixed-positive evidence70% evidence | 19.9/35 Income 24.5% · PAT 100% 71% evidence | 11.1/25 ROA 1.2% · ROE 1.9% · GNPA — 68% evidence | 5.5/20 P/BV 1.53× · P/BV÷ROE 0.81 70% evidence | 13.5/20 RS sector 6.2% · RS bench 0.6% · 1Y 28.9%0 of 7 weeks ahead to 2026-07-02 70% evidence | |
| Exact sum: 19.9 + 11.1 + 5.5 + 13.5 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Invesco Ltd.IVZ | 49.8/100Mixed-negative evidence60% evidence | BREAKING OUT | 19.1/35 Income — · PAT — 26% evidence | 10.4/25 ROA 1% · ROE 2.4% · GNPA — 68% evidence | 7.3/20 P/BV 0.94× · P/BV÷ROE 0.39 70% evidence | 13.0/20 RS sector 8.4% · RS bench 12.4% · 1Y 54.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 10.4 + 7.3 + 13 = 49.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10T. Rowe Price Group, Inc.TROW | 49.7/100Mixed-negative evidence60% evidence | BREAKING OUT | 17.3/35 Income — · PAT — 26% evidence | 15.7/25 ROA 2.8% · ROE 6.1% · GNPA — 68% evidence | 7.5/20 P/BV 2.21× · P/BV÷ROE 0.36 70% evidence | 9.2/20 RS sector -2.8% · RS bench 0.6% · 1Y 10.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 15.7 + 7.5 + 9.2 = 49.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Ares Management CorporationARES | 48.7/100Mixed-negative evidence60% evidence | BREAKING OUT | 20.7/35 Income — · PAT — 26% evidence | 14.1/25 ROA 1.5% · ROE 7.1% · GNPA — 68% evidence | 4.8/20 P/BV 6.11× · P/BV÷ROE 0.86 70% evidence | 9.1/20 RS sector -11.7% · RS bench -9.3% · 1Y -24.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 14.1 + 4.8 + 9.1 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12StepStone Group Inc.STEP | 46.6/100Thin evidence · provisional55% evidence | BASING | 23.2/35 Income 69.7% · PAT — 45% evidence | 13.4/25 ROA 6.9% · ROE 0.5% · GNPA — 68% evidence | 9.8/20 P/BV -9.31× · P/BV÷ROE — 10% evidence | 0.2/20 RS sector -24.7% · RS bench -22.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.2 + 13.4 + 9.8 + 0.2 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Franklin Resources, Inc.BEN | 46.5/100Mixed-negative evidence60% evidence | LEADER | 17.5/35 Income — · PAT — 26% evidence | 8.8/25 ROA 0.4% · ROE 1.8% · GNPA — 68% evidence | 5.8/20 P/BV 1.44× · P/BV÷ROE 0.8 70% evidence | 14.4/20 RS sector 16% · RS bench 20.5% · 1Y 43.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 8.8 + 5.8 + 14.4 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Hamilton Lane IncorporatedHLNE | 45.5/100Mixed-negative evidence76% evidence | TURNING | 15.1/35 Income 6.6% · PAT 24% 71% evidence | 17.8/25 ROA 3.6% · ROE 9.6% · GNPA — 68% evidence | 6.3/20 P/BV 4.75× · P/BV÷ROE 0.49 70% evidence | 6.3/20 RS sector -22.9% · RS bench -21% · 1Y -34.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 17.8 + 6.3 + 6.3 = 45.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 15Corebridge Financial, Inc.this pageCRBG | 44.7/100Thin evidence · provisional55% evidence | BREAKING OUT | 19.1/35 Income 14.6% · PAT -71.3% 45% evidence | 5.2/25 ROA 0% · ROE -0.5% · GNPA — 68% evidence | 9.8/20 P/BV 1.01× · P/BV÷ROE — 10% evidence | 10.6/20 RS sector -7.3% · RS bench -4.4% · 1Y -5.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 5.2 + 9.8 + 10.6 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Principal Financial Group, Inc.PFG | 43.3/100Mixed-negative evidence60% evidence | BREAKING OUT | 15.9/35 Income — · PAT — 26% evidence | 7.5/25 ROA 0.1% · ROE 3.6% · GNPA — 68% evidence | 6.4/20 P/BV 1.91× · P/BV÷ROE 0.53 70% evidence | 13.5/20 RS sector 7.3% · RS bench 11.5% · 1Y 50.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 7.5 + 6.4 + 13.5 = 43.3 · Decision use: Price leads the evidence: RS versus the benchmark is 11.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 17Blue Owl Capital Inc.OWL | 42.6/100Mixed-negative evidence60% evidence | TURNING | 19.5/35 Income — · PAT — 26% evidence | 12.1/25 ROA 1.6% · ROE 1.9% · GNPA — 68% evidence | 4.5/20 P/BV 2.94× · P/BV÷ROE 1.55 70% evidence | 6.5/20 RS sector -22.2% · RS bench -20.4% · 1Y -41.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 12.1 + 4.5 + 6.5 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Brookfield Asset Management Ltd.BAM | 41.6/100Mixed-negative evidence76% evidence | BASING | 16.2/35 Income 21.5% · PAT 10.5% 71% evidence | 15.5/25 ROA 3.3% · ROE 5.3% · GNPA — 68% evidence | 3.4/20 P/BV 9.38× · P/BV÷ROE 1.77 70% evidence | 6.5/20 RS sector -11.6% · RS bench -8.8% · 1Y -15.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 15.5 + 3.4 + 6.5 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Equitable Holdings, Inc.EQH | 37.7/100Mixed-negative evidence76% evidence | BREAKING OUT | 12.0/35 Income -23.4% · PAT -126% 71% evidence | 12.7/25 ROA 0.3% · ROE 24.1% · GNPA — 68% evidence | 3.4/20 P/BV 38.27× · P/BV÷ROE 1.59 70% evidence | 9.6/20 RS sector -8.4% · RS bench -5.6% · 1Y -7.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 12.7 + 3.4 + 9.6 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20TPG Inc.TPG | 36.5/100Mixed-negative evidence64% evidence | TURNING | 16.6/35 Income 11.5% · PAT 100% 71% evidence | 4.4/25 ROA -0.8% · ROE -3.4% · GNPA — 68% evidence | 9.4/20 P/BV 5.73× · P/BV÷ROE — 10% evidence | 6.1/20 RS sector -17.4% · RS bench -15.2% · 1Y -20.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 4.4 + 9.4 + 6.1 = 36.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21KKR & Co. Inc.KKR | 35.7/100Mixed-negative evidence60% evidence | TURNING | 16.8/35 Income — · PAT — 26% evidence | 7.9/25 ROA 0.2% · ROE 2.1% · GNPA — 68% evidence | 4.9/20 P/BV 2.7× · P/BV÷ROE 1.28 70% evidence | 6.1/20 RS sector -16.2% · RS bench -13.9% · 1Y -24.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 7.9 + 4.9 + 6.1 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Brookfield CorporationBN | 35.4/100Mixed-negative evidence76% evidence | ASLEEP | 20.1/35 Income -6.7% · PAT 100% 71% evidence | 8.6/25 ROA 0.7% · ROE 0.5% · GNPA — 68% evidence | 3.7/20 P/BV 2.95× · P/BV÷ROE 5.9 70% evidence | 3.0/20 RS sector -13.3% · RS bench -10.3% · 1Y 3.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 8.6 + 3.7 + 3 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Apollo Global Management, Inc.APO | 31.8/100Adverse evidence64% evidence | ASLEEP | 12.3/35 Income 28.2% · PAT -45% 71% evidence | 5.2/25 ROA -0.5% · ROE -3.9% · GNPA — 68% evidence | 9.7/20 P/BV 3.22× · P/BV÷ROE — 10% evidence | 4.6/20 RS sector -9.9% · RS bench -7% · 1Y -6.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 5.2 + 9.7 + 4.6 = 31.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Blue Owl Capital CorporationOBDC | 27.0/100Adverse evidence62% evidence | BASING | 9.4/35 Income -11% · PAT -50.5% 55% evidence | 10.1/25 ROA — · ROE 0.5% · GNPA — 34% evidence | 4.7/20 P/BV 0.77× · P/BV÷ROE 1.53 70% evidence | 2.8/20 RS sector -19.5% · RS bench -16.9% · 1Y -21%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 10.1 + 4.7 + 2.8 = 27 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25The Carlyle Group Inc.CG | 25.3/100Adverse evidence64% evidence | BASING | 7.1/35 Income -28.9% · PAT -44% 71% evidence | 6.5/25 ROA 0.3% · ROE -2.1% · GNPA — 68% evidence | 9.6/20 P/BV 3.22× · P/BV÷ROE — 10% evidence | 2.1/20 RS sector -18.2% · RS bench -15.9% · 1Y -18.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 7.1 + 6.5 + 9.6 + 2.1 = 25.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Pershing Square Inc.PS | 56.4/100Thin evidence · provisional42% evidence | ASLEEP | 28.6/35 Income 68.8% · PAT 100% 71% evidence | 7.8/25 ROA 1% · ROE -35.8% · GNPA — 68% evidence | 10.0/20 P/BV — · P/BV÷ROE — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 2 weeks ahead 0% evidence |
| Exact sum: 28.6 + 7.8 + 10 + 10 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Ameriprise Financial, Inc.AMP | 54.8/100Thin evidence · provisional46% evidence | BREAKING OUT | 16.6/35 Income — · PAT — 10% evidence | 16.4/25 ROA — · ROE 17.9% · GNPA — 34% evidence | 7.1/20 P/BV 6.48× · P/BV÷ROE 0.36 70% evidence | 14.7/20 RS sector -0.2% · RS bench 3.2% · 1Y 9.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 16.4 + 7.1 + 14.7 = 54.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Northern Trust CorporationNTRS | 51.9/100Thin evidence · provisional46% evidence | LEADER | 18.4/35 Income — · PAT — 10% evidence | 12.5/25 ROA — · ROE 6% · GNPA — 34% evidence | 8.6/20 P/BV 1.99× · P/BV÷ROE 0.33 70% evidence | 12.4/20 RS sector 7% · RS bench 11.2% · 1Y 45.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 12.5 + 8.6 + 12.4 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Ares Capital CorporationARCC | 38.0/100Thin evidence · provisional46% evidence | BASING | 16.5/35 Income — · PAT — 10% evidence | 10.6/25 ROA — · ROE 1.2% · GNPA — 34% evidence | 6.0/20 P/BV 0.96× · P/BV÷ROE 0.8 70% evidence | 4.9/20 RS sector -13.5% · RS bench -10.6% · 1Y -12.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 10.6 + 6 + 4.9 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Corebridge Financial, Inc.'s stock price today?
Corebridge Financial, Inc. trades at $31.6, −8.4% over the past year. The company is valued at $14.0 B. The stock sits at 73% of its 52-week range of $22–$35, +10.0% versus its 200-day average. On the tape, the price is topping out, 6 weeks in. — as of 5 August 2026.
What were Corebridge Financial, Inc.'s latest quarterly results?
Corebridge Financial, Inc. reported total income of $4.0 B and a net loss of $0.1 B for the Mar 26 quarter. Earnings per share were $−0.11. The net margin was −1.5%, 17.0 pp higher than a year earlier. — as of 5 August 2026.
What is Corebridge Financial, Inc.'s revenue?
Corebridge Financial, Inc. reported revenue of $4.0 B in the Mar 26 quarter, +10.9% year on year. For the full FY25 fiscal year, revenue was $18.5 B (−1.2%). Over the last 4 years revenue compounded at −5.6% a year. — as of 5 August 2026.
What is Corebridge Financial, Inc.'s profit?
Corebridge Financial, Inc. earned $−0.1 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.4 B. The net margin ran −1.5% in the latest quarter. — as of 5 August 2026.
What is Corebridge Financial, Inc.'s market cap?
Corebridge Financial, Inc.'s market capitalisation is $14.0 B at a stock price of $31.6. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Corebridge Financial, Inc.'s P/BV ratio?
Corebridge Financial, Inc. trades at a P/BV of 1.4×, at the 52nd percentile of its own 4-year range, against a long-run median of 1.4×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Corebridge Financial, Inc. pay a dividend?
Yes — Corebridge Financial, Inc. declared $0.25 per share for Mar 26, and $0.97 per share across the last four reported quarters. The latest quarter is up 4.2% on the same quarter a year earlier. — as of 5 August 2026.
What is Corebridge Financial, Inc.'s dividend per share?
Corebridge Financial, Inc.'s most recently declared dividend is $0.25 per share for Mar 26, giving $0.97 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Corebridge Financial, Inc.'s dividend yield?
Corebridge Financial, Inc.'s trailing dividend yield is 3.07%: $0.97 declared per share across the last four reported quarters, against a share price of $31.6. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Corebridge Financial, Inc. overvalued?
On its own history, Corebridge Financial, Inc. looks mid-range against its own history: its P/BV of 1.4× sits at the 52nd percentile of its 4-year range (long-run median 1.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
How is Corebridge Financial, Inc. performing?
Corebridge Financial, Inc. is topping out, 6 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Corebridge Financial, Inc. in?
Deteriorating — profit and EPS growth are shrinking (profit growth −70.4% latest against +111.5% at its 12-quarter best), ROE holding at 1.8%. The read comes from the last 12 quarters of growth (revenue growth +14.6% latest, profit growth −70.4% latest, eps growth −63.6% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Corebridge Financial, Inc. in an uptrend?
It is stalling — the price is topping out (week 6 of stage 3), trading +10.0% versus its 200-day average and at 73% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Corebridge Financial, Inc. beating the market?
On recent form, yes — Corebridge Financial, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.9 years the stock moved +53% against the S&P 500's +100% — behind the index over the full window. — as of 5 August 2026.
Will Corebridge Financial, Inc.'s stock price go up?
This page publishes no price forecast for Corebridge Financial, Inc. What it measures instead: the stock price is $31.6, the price is topping out 6 weeks in. Its P/BV of 1.4× sits at the 52nd percentile of its own 4-year range. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Corebridge Financial, Inc.?
Somewhat — short interest is 8.0% of Corebridge Financial, Inc.'s tradable float, about 4.5 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Is Corebridge Financial, Inc.'s loan book healthy?
We do not hold quarterly loan-book quality numbers for Corebridge Financial, Inc., so this page says that plainly. The cleanest available reads are revenue growth (−1.2% in FY25) and the net margin on it (−1.5%) — as of 5 August 2026.
Where is Corebridge Financial, Inc. in its business cycle?
Corebridge Financial, Inc.'s FY25 net margin was −2.1%, against a 5-year band of −2.1%–39.4%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran −1.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Corebridge Financial, Inc. story?
The sharpest disagreement: the price moved −8.4% in a year while annual EPS moved −118.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Corebridge Financial, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Corebridge Financial, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.